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Abstract
Background: Postoperative radioactive iodine (RAI) administration is widely
utilized in patients with differentiated thyroid cancer. While beneficial in select
patients, it is critical to recognize the potential negative sequelae of this treat-
ment. The prevention, diagnosis, and management of the salivary and lacrimal
complications of RAI exposure are addressed in this consensus statement.
Methods: A multidisciplinary panel of experts was convened under the auspices
of the American Head and Neck Society Endocrine Surgery and Salivary Gland
Sections. Following a comprehensive literature review to assess the current best
evidence, this group developed six relevant consensus recommendations.
Results: Consensus recommendations on RAI were made in the areas of
patient assessment, optimal utilization, complication prevention, and compli-
cation management.
Conclusion: Salivary and lacrimal complications secondary to RAI exposure
are common and need to be weighed when considering its use. The recommen-
dations included in this statement provide direction for approaches to mini-
mize and manage these complications.
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1 | INTRODUCTION
The incidence of thyroid cancer has steadily increased
over the last four decades. This has occurred without a
similar corresponding rise in mortality rates.1 Radioactive
iodine (RAI) treatment has been employed for patients
with thyroid cancer since the 1940s. In the United States,
the proportion of patients with differentiated thyroid can-
cer who received RAI treatment rose from 40% in 1990 to
56% in 2008.2 Since then, however, in at least some
regions, this trend has started to reverse.3 Based upon
recent research, the 2015 edition of the American Thy-
roid Association guidelines on thyroid nodules and
cancer recommend remnant ablation with RAI in fewer
circumstances and, when utilized, at lower administered
activities.4 Currently, postoperative RAI administration is
recommended for all patients with high-risk differenti-
ated thyroid cancer for whom it may improve survival,
and for a subset of patients with intermediate-risk thyroid
cancer who may be at higher risk of recurrence. Despite
the availability of these evidence-based recommendations
on the optimal utilization of RAI, wide variability exists
in its usage.2
From an oncologic perspective, select patients with thy-
roid cancer benefit from RAI therapy. However, it is critical
to acknowledge the potential negative sequelae of this
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treatment. While it is widely recognized that RAI can have
an adverse impact on the salivary glands, the precise inci-
dence and presentation of salivary gland dysfunction is less
clearly understood. Furthermore, while less common, the
lacrimal glands and nasolacrimal system can also be
impacted leading to a range of ocular complaints.
2 | METHODS
In this clinical consensus statement, we review the poten-
tial sequelae of RAI on the salivary and lacrimal glands
and lacrimal outflow system. The current state of knowl-
edge regarding the incidence and presentation of RAI-
induced salivary gland disease and lacrimal dysfunction
as well as risk factors for disease development are dis-
cussed. This statement also provides direction regarding
how best to mitigate those risks, as well as state-of-the-
art recommendations for the optimal management of
patients with xerostomia, sialadenitis, or epiphora. We
also introduce new innovations in salivary gland manage-
ment including the emerging field of sialendoscopy.
Reflecting the range of physicians involved in the care
of patients undergoing RAI treatment, this consensus
statement was purposely developed by convening a mul-
tidisciplinary group of authors. Experts from the Endo-
crine Surgery Section and Salivary Gland Section of the
American Head and Neck Society (AHNS) were joined by
leading physicians invited from ophthalmology, endocri-
nology, nuclear medicine and general surgery. Addition-
ally, several of the world's authorities on salivary gland
diseases and their management (including sialendoscopy)
were included in the author panel.
Evidence-based support for the recommendations was
drawn from the literature and the authors' expert opin-
ions. Reviews of the literature, performed to provide criti-
cal reference material for the author panel, were
conducted in August 2018. Computerized and manual
searches were performed to identify relevant publica-
tions. Computerized searches for studies published
between January 1966 and August 2018 were performed
using PubMed, Cochrane Library, Cochrane Central Reg-
ister of Controlled Trials, and Medline. First, a search
using the terms radioiodine, RAI, 131I, and thyroid cancer
was conducted. These articles were then cross-referenced
with those found with the search terms: salivary gland,
sialadenitis, salivary gland dysfunction, sialendoscopy,
xerostomia, lacrimal gland, lacrimal outflow, and
nasolacrimal duct. These studies were limited to those
published in English examining humans. Members of the
expert panel were also asked to supplement this search
by submission of additional references they thought were
most relevant and of high quality.
The specific goals of the clinical consensus statement
were reviewed with the entire group. Draft statements and
relevant text were circulated among these members for
commentary. These comments were then were incorpo-
rated by the lead author (M.S.) and a final draft of the man-
uscript and recommendations was distributed to all
authors for review. Recommendations were categorized
according to the American College of Physicians grading
system for evidence-based guidelines.5 After the author
panel provided its approval, it received final approval from
the AHNS Education Service and thus has full AHNS orga-
nizational support as a statement of the AHNS.
3 | NORMAL SALIVARY GLANDS:
ANATOMY AND PHYSIOLOGY
The primary salivary glands in humans are the paired
parotid, submandibular, and sublingual glands.6 In addi-
tion, distributed throughout the oral cavity and pharynx
are numerous minor salivary glands. The parotid glands
produce saliva, representing approximately 30% of total
daily production, primarily during meals. The subman-
dibular (60%), sublingual (5%) and minor salivary (5%)
glands are responsible for the basal production of saliva
necessary for continuous upper aerodigestive tract hydra-
tion and lubrication.
The fundamental unit for all salivary tissue consists
of acini producing saliva that then drains into a progres-
sively widening ductal system. Acinar cells have special-
ized functions and are classified according to the quality
of the saliva that they produce: serous, mucinous, or
mixed. These cells are present in the major salivary
glands in different distributions: the parotid glands are
predominately composed of serous acini, the sublingual
glands primarily mucinous acini, and the submandibu-
lar glands contain an equal mix mucinous and serous
acini.
The 1-2 L of saliva produced daily is made up of
approximately 99% water. Saliva also contains a complex
blend of organic substances (including proteins, enzymes,
mucin, and immunoglobulins) and inorganic molecules
such as iodine, sodium, potassium, and calcium. The
saliva can contain iodide levels that are 7-700 times
plasma iodide levels.7,8
Saliva has a multitude of functions, including lubrica-
tion of food and oral cavity structures (critical for dental
health), facilitation of chewing, tasting, and swallowing,
initiating digestion, assisting in antimicrobial efforts, and
optimizing taste receptor function. The precise role of
iodine in these tasks remains unclear, although antioxi-
dant functions have been postulated to play an important
role in oral immune defense.9 When salivary production
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is impaired all of these functions can be compromised,
resulting in xerostomia, decreased taste, impaired
swallowing and digestion, and increased susceptibility to
dental and periodontal disease.
4 | PATHOPHYSIOLOGY
RAI-associated parotitis was first reported by Rigler and
Scanlon.10 Despite this long known association, no pre-
cise understanding of the exact pathophysiology of RAI-
induced salivary gland dysfunction has been elucidated.
The sodium/iodide symporter, which is highly
expressed along the basolateralmembrane of epithelial cells
of the striated salivary ducts (as opposed to the acini), allow
concentration of iodine in the saliva.11,12 After uptake and
concentration within the cytoplasm of these ductal cells,
iodide is later secreted by the intralobular ductal epithe-
lium into the salivary gland ducts. When RAI is adminis-
tered and concentrated into salivary gland cells, damage
to the ductal epithelium and surrounding tissue (includ-
ing adjacent vascular endothelial damage) may occur
immediately or in a delayed fashion. Ultimately, histo-
logic changes associated with RAI exposure include peri-
acinoductal inflammation and fibrosis.13,14
In the immediate phase, an increase in capillary per-
meability results in the leakage of plasma proteins and
electrolytes into the surrounding interstitial tissues.7 The
intralobular ducts lose their ability to filter and prevent
plasma proteins from entering the saliva. This results in
elevated protein and sodium chloride levels along with
decreased phosphate and prostaglandin levels in the
saliva.7,8,13
Serous salivary cells concentrate iodide to a greater
extent than mucinous acini, and as noted, the parotid
glands have the highest concentration of serous cells.15
Consequently, although all salivary glands are involved
in RAI transport into the saliva, the parotid glands are
most adversely affected by RAI.16 Additionally, the
sodium iodide symporters located in submandibular
glands continuously transport RAI out of the parenchy-
mal cells and into the ducts. This contrasts with the
parotid glands in which symporter function is less contin-
uous. Thus, transit time in the parotid glands is longer,
leading to greater exposure of the parotid parenchyma to
RAI.17,18 As a result, these glands are most susceptible to
the adverse effects of RAI.
An early response to irradiation can result in
decreased salivary flow rates within the first week follow-
ing RAI treatment.11,19 Narrowing of the duct lumen
from inflammation results in the formation of a jelly-like
plug consisting of radiation induced inflammatory cells
and mucus. If acute sialadenitis results from this obstruc-
tion, swelling and pain are most marked during eating
and periods of increased salivary production.7,20,21 Within
a few days, resolution of this acute inflammatory phase
occurs and initial symptoms subside. The sensation of
oral dryness can occur when a person's normal,
unstimulated flow rate is reduced by 45%-50% and is
dependent on the extent of parenchymal RAI damage.17
The exact etiology for some of the other frequently seen
sequelae of RAI, such as distortion or loss of taste,
remains unclear.
The lacrimal glands are embryologically related to the
major salivary glands and also contain the sodium/iodide
symporter. There is a small body of literature evaluating
the effect of RAI treatment on lacrimal gland function,
manifesting typically as eye dryness, pruritus and other
secondary ocular surface abnormalities. Often patients
with ocular symptoms demonstrate minimal or no objec-
tive findings that correlate with their disease.22-25 Fortu-
nately, in most patients, these ophthalmic symptoms
tend to decrease over the first 3 years after treatment.25
Epiphora can also occur after RAI treatment through
several mechanisms. In patients with dry eyes, there is a
reflexive increase in tear production without an accompa-
nying increase in ocular surface mucous and oil, resulting
in tear overflow. In addition, frank lacrimal outflow
obstruction may also occur in patients receiving high
activity RAI. Both mechanisms are responsible for RAI-
associated epiphora.26
Nasal symptoms, including dryness, pain, and epistaxis,
can also occur after treatment with RAI. Three months after
RAI treatment, approximately 10% of patients complain of
nasal symptoms.27 While cells within the nasolacrimal
ducts express the sodium iodine symporter, nasal tissues do
not.24,28-30 Thus, the mechanism of nasal-induced RAI
symptoms is still not entirely understood.
The risk of developing a secondary primary malig-
nancy associated with treatment with RAI is one of the
primary concerns of physicians and patients.31-37 Several
cancer database epidemiological investigations have ana-
lyzed the risk of secondary primary malignancy develop-
ment. The findings of these studies are divergent. While
some have shown no significant increased risks with RAI
exposure,32,38,39 numerous others have demonstrated a
significantly elevated risk, at least of salivary gland malig-
nancies, in selected cohorts.31,33-36,40-42
Given the concentration of RAI in salivary gland tis-
sue, these glands are potentially particularly at risk of
developing a secondary primary malignancy. RAI can
theoretically induce genetic alterations in salivary gland
cells, resulting in tumor development. There have been
at least six reported cases of mucoepidermoid carcinoma
of the salivary glands following RAI exposure.43-46 How-
ever, more generally, the risk of salivary gland malig-
nancy appears to be increased.40-42 Two studies have
reported that when compared to similar patients not
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treated with RAI, those with exposure had an increased
standardized incidence ratio of 11.13:34.1.40,41
It does appear that there is a correlation between RAI
dosing and risk of secondary primary malig-
nancy.31,35-37,47,48 Additionally, patients treated with RAI
at younger ages have been shown to be those most at risk
of development of secondary primary malignancy.33,48,49
A number of studies have shown that patients exposed to
RAI are at increased risk of leukemia, with reported stan-
dardized incidence ratios of between 2.74 and 5.68.33,35,41
The risk of hematologic malignancies specifically appears
to increase with age, smoking, and radiation expo-
sure.41,49 There is retrospective evidence that suggests
that increasing activity of RAI may be associated with
clonal hematopoiesis, a precursor clonal state that may
eventually lead to the development of myeloid malignan-
cies.50 These findings must be viewed in the context of
other studies that have demonstrated that patients with
thyroid cancer are at greater risk of developing a second-
ary primary malignancy irrespective of treatment
received.51,52 Clearly further research is needed to more
comprehensively understand the risks of RAI as it relates
to secondary primary malignancy.
Recommendation #1
Given the potential for salivary and lacrimal side
effects as well as secondary primary malignancy, patients
in whom RAI therapy is being considered should receive
pretreatment education regarding the prevalence and
nature of these complications. Xerostomia, sialadenitis,
dry eyes, epiphora, nasal symptoms and, in rare
instances, secondary primary malignancy should be dis-
cussed. [Strong recommendation, moderate-quality
evidence]
Recommendation #2
Physicians should be aware that secondary primary
malignancies can be associated, rarely, with the use of RAI
and relates to RAI activity and patient age. Given this small
but possible risk of a secondary malignancy, including of
the salivary glands, kidneys and bone marrow, judicious,
evidence-based use of RAI is warranted. In addition, these
risks should be considered when determining optimal
follow-up. [Weak recommendation, low-quality evidence]
5 | INCIDENCE/RISK
The reported incidence of salivary gland dysfunction after
treatment with RAI appears quite common but varies sig-
nificantly between studies because of heterogeneous
patient cohorts, variability in administered activity and
number of treatments, timing of salivary gland assess-
ment, definition of salivary gland dysfunction, and
method of determining dysfunction.
In the immediate post-treatment phase, the incidence
of acute sialadenitis ranges from 10% to 41%.53-56 One
year after RAI exposure sialadenitis is reported in 5%-43%
of patients.57,58 Sialadenitis affects the parotid glands in
59%-81% of cases and when involved both parotid glands
are typically affected. The submandibular glands are
affected in 16%-46% of cases.59
Xerostomia symptoms appear between 3 months and
1 year after RAI treatment. The reported incidence varies
between 15% and 54%.12,60 Studies show an apparent
diminution of prevalence with time: 17%-33% at 1 year,
15% at 3 years, and 13% at 7 years.25,57 Importantly, in
the general population, xerostomia has an overall preva-
lence ranging from 8% to 13%.61,62
Taste alterations also appear to be common following
RAI therapy. The prevalence of dysgeusia ranges from
13% to 27%.7,57 This typically occurs soon after treatment.
While in most patients, this issue resolves, in some
patients, the taste change is permanent.
Ocular symptoms appear between 2 months and
1 year after RAI treatment and their prevalence ranges
from 8% to 25.3%23,25 for dryness and between 2.5% and
11%23,63 for epiphora. Over time, the incidence of both of
these symptoms appears to decrease.25,64
A number of risk factors for the development of sali-
vary dysfunction after RAI have been identified (Table 1).
The risk of experiencing symptoms of sialadenitis and
xerostomia appears to be activity-dependent and cumula-
tive with multiple RAI exposures.15,17 Two studies suggest
that the inflection point for a marked increase in risk
occurs at approximately 100 mCi for xerostomia20 and
150 mCi for sialadenitis.56 Importantly, the risk of develop-
ing salivary gland related complications is significantly less
with administration of a single activity of 30 mCi.58,65
Age and gender have also been reported to impact sal-
ivary gland function, with women and those over age
TABLE 1 Risk factors that have been associated with salivary
gland dysfunction following RAI exposure
Risk factors for salivary gland dysfunction
RAI dosage >100 mCi for xerostomia
RAI dosage >150 mCi for sialadenitis
Use of thyroid hormone withdrawal rather than recombinant
TSH for preparation for RAI treatment
Age > 45 years
Shorter intervals between exposures
Medications that induce xerostomia
Comorbid diseases: Sjögren's syndrome, IgG4-related disease,
and so on
Abbreviations: Ig, immunoglobulin; RAI, radioactive iodine; TSH,
thyroid stimulating hormone.
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45 years old at increased risk of salivary gland dysfunc-
tion after RAI exposure.15 Van Nostrand suggested that
the variability of sialadenitis is due to numerous factors,
including dosage, intervals between treatments, factors
affecting gland uptake, comorbid disease, xerostomic
medications, and preventive measures.59
Several studies have concluded that the use of recom-
binant thyroid stimulating hormone (TSH) to facilitate
RAI treatment seems to reduce the risk of developing sal-
ivary gland dysfunction. Utilization of recombinant TSH
for preparation of RAI ablation as compared to thyroid
hormone withdrawal is associated with a lower incidence
of salivary gland dysfunction.65-67
Risk factors for nasolacrimal side effects also include
higher activity of RAI.28 A single study found an inverse
relationship between body mass index and risk of
nasolacrimal symptoms.28 Interestingly, in contrast to other
symptoms, studies of dry eyes have shown no correlation
between complaints and administered activity of RAI.
Recommendation #3a
Given the association between administered activity
of RAI, particularly greater than 100 mCi, and the fre-
quency and severity of side effects, the minimum effec-
tive, individualized RAI activity should be utilized.
Thyroid remnant ablation with 30 mCi of RAI has signifi-
cantly less risk of inducing complications. Additionally,
in patients with thyroid cancer, whose tumors are consid-
ered iodine-refractory, unless efforts at redifferentiation
are attempted, RAI use should be avoided. [Strong rec-
ommendation, moderate-quality evidence]
Recommendation #3b
The use of recombinant TSH rather than thyroid hor-
mone withdrawal to prepare for RAI therapy appears to
reduce both the risk of salivary and lacrimal gland com-
plications. This should be considered when determining
the optimal protocol for patient RAI preparation. [Weak
recommendation, low-quality evidence]
Recommendation #3c
Other factors such as age, interval between RAI treat-
ments, factors relating to salivary gland uptake, preexisting
salivary gland disease, and xerostomic medication impact
the risk of RAI related complications. These should be con-
sidered when determining the risk-benefit calculation of
RAI treatment for individual patients. [Strong recommen-
dation, low-quality evidence]
6 | PREVENTION
Given the frequency of symptomatic sequelae of treat-
ment with RAI, a range of approaches has been utilized
by clinicians in an attempt to reduce their incidence and
severity. In addition to aggressive hydration,
interventions that are often recommended include the
use of medications, supplements, sialagogues, and
massage.
6.1 | Amifostine
Amifostine has been used as a radioprotectant for patient
with head and neck cancer receiving external beam radi-
ation and has been touted as a promising preventive ther-
apy for sialadenitis in patients receiving RAI treatment.
In a comprehensive review of the medical literature in
2010, Ma et al reviewed 92 pertinent studies and found
two randomized controlled trials involving the compara-
tive use of amifostine and salivary stimulants to prevent
post-RAI sialadenitis.68-70 Their meta-analysis found no
significant radioprotective effects on the salivary glands
of the 130 patients in these two trials.
6.2 | Sialagogues
The use of sialagogues, such as sour/lemon candies or
lemon juice, which increase salivation appears to have a
protective effect on the salivary glands in patients treated
with RAI.71 Greater salivation results in a more rapid
transit of the RAI through the salivary glands. Theoreti-
cally, a shorter exposure period with less radioactive
absorption reduces the risk of salivary gland injury.
While sialagogues after RAI exposure are widely rec-
ommended, several critical questions regarding their
optimal use remain controversial. Significant disagree-
ment exists concerning the appropriate time to initiate
their consumption after exposure. Additionally, once
initiated, the ideal frequency of use once started is
debated.
One study suggested that lemon candy stimulation
should only begin 24 hours after RAI dosing, because
early administration actually increases the salivary
glands' avidity for RAI accumulation, whereas later use
increases RAI clearance from the salivary glands.72 This
cohort of 255 patients treated with an average of 105 mCi
of RAI after thyroid hormone withdrawal was divided
into two lemon drop treatment groups, one starting on
1-2 lemon drops every 2-3 hours immediately after receiv-
ing 131I and another who started with the candy 24 hours
after treatment. Of the group who started the candy
immediately, 64% experienced sialadenitis, hypogeusia,
taste loss or dry mouth as opposed to only 37% of patients
who were started 24 hours after RAI administration.
However, other studies have provided data that do not
support these results and imply that immediate and
repetitive sialagogue administration may be best.73
SINGER ET AL. 3451
Van Nostrand et al demonstrated that the pharmaco-
kinetics of iodine in the parotid glands changes dramati-
cally after administration of sialagogues and that this
finding has potential management consequences.74 In
23 patients, they demonstrated that after sialagogue
administration, the iodine in the parotid gland was rap-
idly and significantly secreted. Interestingly, the parotid
glands re-accumulated iodine back to their pre-
sialagogue level in 21-40 minutes. However, the same
rapid and significant secretion followed repeated admin-
istration of the sialagogues. Van Nostrand et al calculated
that with repeated administration of the sialagogues the
absorbed dose of radiation to the parotid gland would be
reduced by as much as 37%-45%, supporting the use of
sialagogues continuously during the day and intermit-
tently at night.59,74 Nakada et al subsequently validated
the pharmacokinetics of iodine in the salivary glands as
reported by Van Nostrand et al.75
As noted earlier, debate also exists over the optimal
time to start the use of sialagogues following RAI expo-
sure. Nakada et al assert that due to a “rebound effect” of
increased radioiodine accumulation from salivation,
avoiding sialagogues during the first 24 hours after ther-
apy would reduce side effects. Kulkarni et al evaluated
whether or not a “rebound” occurs after administration
of sialagogues by performing a prospective study in
which I-123 scans were performed with and without sial-
agogues with the patients being their own control.76 In
this study, no “rebound effect” was identified, suggesting
that sialagogues use should be initiated immediately.
6.3 | Supplements
Vitamin E has also been assessed as a possible protectant
from the side effects of RAI. One study examined the
potential benefit of pretreatment with vitamin E supple-
ment.77 The groups receiving vitamin E exhibited statisti-
cally better salivary gland function by scintigraphy when
compared to the control group. A second smaller study
resulted in similar outcomes.78
The use of selenium as a protective agent has also
been considered. One small study suggested that it might
provide a benefit in terms of salivary gland symptoms,
particularly at 6 months.79 A separate randomized trial
on 72 patients receiving vitamin C after RAI did not show
any benefit regardless of the timing.80
6.4 | Massage
Massage of the glands, often recommended to any patient
with salivary gland issues, potentially appears to be
effective in patients receiving RAI as well. A controlled
study of 60 patients demonstrated its efficacy, especially
in younger patients.81
Recommendation #4a
The use of lemon candies/juice and massage as RAI
protectants should be considered. The exact optimal time
to start, frequency, duration, and particular sialagogue
and method of massage to use remains unclear. [Weak
recommendation, moderate-quality evidence]
Recommendation #4b
There is insufficient data to recommend the use of
other interventions, including the use of amifostine,
vitamin E, selenium, or vitamin C as RAI protectants.
[Weak recommendation, low-quality evidence]
7 | EVALUATION AND
MANAGEMENT
7.1 | Diagnosis
The use of patient surveys to assess subjective complaints
of salivary dysfunction, whether xerostomia or sialadenitis,
has been studied extensively. Although many of these focus
solely on xerostomia,82-85 others specifically include items
focused on sialadenitis.27,64,79,86-88
There are a host of options available to objectively
evaluate the function of the salivary glands and deter-
mine anatomic causes for related complaints.
7.2 | Salivary gland scintigraphy
Salivary gland scintigraphy can be employed to deter-
mine the functionality of the salivary glands.25 A correla-
tion has been demonstrated between measured salivary
gland function and sialadenitis55 and xerostomia symp-
toms.15,17 After RAI treatment with high activities, the
uptake or excretion of the salivary glands is abnormal in
approximately 70% of patients at 18-20 months following
exposure.15,89 Scintigraphy allows early detection of glan-
dular dysfunction, before sialometry becomes abnormal.
Importantly, however, scintigraphy has no role in evalu-
ating strictures or sialoliths.
7.3 | Sialometry/sialography
Sialometry, a functional exam, and sialography, an ana-
tomical study, were historically used to evaluate patients
with salivary disorders. Due to inconsistent results,
sialometry is no longer employed. Sialography is the classi-
cal method to assess salivary ductal pathologies, with
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excellent sensitivity for detection of sialolithiasis and, to a
lesser extent, stenosis.90,91 However, because of the associ-
ated risks, this imaging modality has been largely aban-
doned in favor of magnetic resonance (MR) sialogram (see
below).
7.4 | Ultrasound
Ultrasound is a cost-effective and reliable method to
image the salivary glands. It is considered a first-line
modality in cases of sialadenitis, with good sensitivity for
stone detection (71.9%),90 even as small as 2-3 mm (accu-
racy of 94%),91 and identification of stenosis.92,93 How-
ever, ultrasound has limitations for the diagnosis of
strictures.90,91 Importantly, the changes that occur in the
ultrasound features of the major salivary glands after RAI
do not have a statistically significant association with the
development of xerostomia94 or sialadenitis.95
7.5 | Computed tomography
Computed tomography is a widely used method to assess
for the presence and location of salivary stones. However,
it has limited sensitivity for identifying salivary strictures
such as those present in RAI-related chronic sialadenitis.
7.6 | MR sialogram
MR sialogram with its T2-weighted sequences allows for
the generation of excellent quality three-dimensional
reconstructions of the salivary gland ducts and their
pathologies. This is done without any ductal injection of
contrast media. MR sialogram is an excellent method to
assess ductal stenosis and chronic sialadenitis.96,97 How-
ever, it is expensive and time-consuming.
7.7 | Sialendoscopy
Sialendoscopy offers both diagnostic and therapeutic
functions. First described in the early 1990s, the tech-
nique has gained wider adoption among otolaryngolo-
gists since the turn of the century.
Initially, salivary probes, specifically designed for this
procedure, are introduced through the respective gland's
duct ostium. The duct papilla is cannulated and is
sequentially dilated. After adequate dilation, a
sialendoscope (with a diameter of only between 0.89 and
1.6 mm) can then be introduced to begin the endoscopy.
These miniature endoscopes can be used for both diag-
nostic and interventional purposes (Figure 1).
Sialendoscopy provides 100% sensitivity for the assess-
ment of salivary strictures and represents an excellent first-
line diagnostic tool in cases of RAI sialadenitis.90 As long
as the sialendoscope passes the given stricture, they can be
theoretically dilated mechanically or via fluid pressure.
7.8 | Lacrimal evaluation
Patients with complaints of dry eye or epiphora should
be referred to an ophthalmologist for examination includ-
ing slit lamp biomicroscopy, to assess the cornea and tear
film, as well as Schirmer testing of tear production. In
patients with epiphora, the lacrimal outflow system
should be probed and irrigated to assess for partial or
complete nasolacrimal obstruction. Dacryoscintigraphy
or dacryocystography may be useful in determining the
specific location of nasolacrimal obstruction if there is
uncertainty after clinical evaluation.
8 | TREATMENT
8.1 | Xerostomia
Management of xerostomia consists of conservative inter-
ventions with adequate hydration, tobacco avoidance and
appropriate oral hygiene.98 Systemic salivary stimulants
such as pilocarpine and cevimeline and several topical
medications can also help these patients, although they
may be associated with unsatisfactory systemic side
effects.99 While the use of sour candies, sugar-free
FIGURE 1 To perform diagnostic and interventional
sialendoscopy specialized, miniature sialendoscopes and
instruments (as shown) are utilized [Color figure can be viewed at
wileyonlinelibrary.com]
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chewing gum and lemon juice are widely recommended,
there is limited data demonstrating the actual value of
these interventions.59 Importantly, particular attention
should be paid to the possible development of oral candi-
diasis in patients with xerostomia as its colonization is
facilitated by salivary flow reduction.7
8.2 | Acute sialadenitis
Acute sialadenitis is characterized by the rapid onset of
salivary gland inflammation, which can be associated
with pain, tenderness, induration, and swelling.
The treatment of acute sialadenitis should consist of
nonsteroidal anti-inflammatory medications or oral corti-
costeroid therapy for the symptomatic period. In cases in
which there is persistent painful swelling, erythema or
pus seen at the papilla, a broad-spectrum antibiotic, such
as amoxicillin-clavulanate or clindamycin, should be pre-
scribed as the typical infectious flora includes gram-
positive and anaerobic organisms.59
To date, there is no evidence in the literature regard-
ing the utility of massage or warm compresses for acute
sialadenitis. Importantly, sialagogues in the acute phase
of sialadenitis are contraindicated as they can worsen the
symptoms.
8.3 | Chronic sialadenitis
Chronic sialadenitis, typified by repeated episodes of sali-
vary gland swelling and pain (frequently occurring with
meals), can either result from recurrent episodes of acute
sialadenitis damaging the salivary gland or can be due to
a progressive reduction in function of the glands due to
ductal strictures.7 This second scenario is typical of
patients following RAI exposure.
In contrast to acute sialadenitis treatment, an under-
lying important dynamic in the treatment of chronic
sialadenitis is stimulation of the hypofunctional salivary
tissue. Therefore, all salivary stimulants are potentially
beneficial in these patients. Additionally, due to the pre-
disposition to dental caries in the setting of xerostomia,
oral hygiene should be optimized.100
8.4 | Sialendoscopy
Sialendoscopy offers a minimally invasive approach to
address strictures in a safe and effective manner.101 After
diagnostic assessment with a sialendoscope, strictures
can be immediately addressed. Repeated sialendoscopies
may be offered for persistent or recurrent symptoms.102
With a sialendoscope, instillation of a NaCl solution
allows dilation of the ductal branches, which can then
be visually inspected. When seen, strictures appear
white and fibrotic (Figures 2 [normal duct] and B [stric-
ture]). At the end of a sialendoscopy procedure, a corti-
costeroid solution can be infused into the duct
system.103
In a systematic review from 2017, in patients
complaining of sialadenitis symptoms, 89.3% reported
improvement after sialendoscopy.104 In regard to
xerostomia, the data have been inconsistent regarding
the benefits of sialendoscopy. Some studies have shown no
improvement in oral dryness87,105 while others have dem-
onstrated that in some patients subjective xerostomia com-
plaints decreased.106 It does appear that earlier intervention
with sialendoscopy provides improved outcomes.107 This
likely is due to the greater ease of dilating less severe stric-
tures. Several studies have examined the impact of
sialendoscopy on RAI-induced salivary gland symptoms in
patients who have failed medical management.105,108,109
These series have reported that sialendoscopy is often
FIGURE 2 A, An
endoscopic view of a normal
appearing duct. B, An
endoscopic view of a strictured
duct following radioiodine
exposure. The duct is reduced in
caliber and exhibits white,
fibrotic walls [Color figure can
be viewed at
wileyonlinelibrary.com]
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TABLE 2 List of recommendations
Recommendation #1 Given the potential for salivary and lacrimal side effects
as well as secondary primary malignancy, patients in
whom RAI therapy is being considered should
receive pretreatment education regarding the
prevalence and nature of these complications.
Xerostomia, sialadenitis, dry eyes, epiphora, nasal
symptoms and, in rare instances, secondary primary
malignancy should be discussed.
Strong recommendation, moderate-
quality evidence
Recommendation #2 Physicians should be aware that secondary primary
malignancies can be associated, rarely, with the use
of RAI and relates to RAI activity and patient age.
Given this small but possible risk of a secondary
malignancy, including of the salivary glands, kidneys
and bone marrow, judicious, evidence-based use of
RAI is warranted. In addition, these risks should be
considered when determining optimal follow-up.
Weak recommendation, low-quality
evidence
Recommendation #3a Given the association between administered activity of
RAI, particularly greater than 100 mCi, and the
frequency and severity of side effects, the minimum
effective, individualized RAI activity should be
utilized. Thyroid remnant ablation with 30 mCi of
RAI has significantly less risk of inducing
complications. Additionally, in patient with thyroid
cancer, whose tumors are considered iodine-
refractory, unless efforts at redifferentiation are
attempted, RAI use should be avoided.
Strong recommendation, moderate-
quality evidence
Recommendation #3b The use of recombinant TSH rather than thyroid
hormone withdrawal to prepare for RAI therapy
appears to reduce both the risk of salivary and
lacrimal gland complications. This should be
considered when determining the optimal protocol
for patient RAI preparation.
Weak recommendation, low-quality
evidence
Recommendation #3c Other factors such as age, interval between RAI
treatments, factors relating to salivary gland uptake,
preexisting salivary gland disease, and xerostomic
medication impact the risk of RAI-related
complications. These should be considered when
determining the risk-benefit calculation of RAI
treatment for individual patients.
Strong recommendation, low-quality
evidence
Recommendation #4a The use of lemon candies/juice and massage as RAI
protectants should be considered. The exact optimal
time to start, frequency, duration, and particular




Recommendation #4b There are insufficient data to recommend the use of
other interventions, including the use of amifostine,
vitamin E, selenium, or vitamin C as RAI protectants.
Weak recommendation, low-quality
evidence
Recommendation #5 In patients experiencing symptoms after RAI exposure
timely referral, to an otolaryngologist for salivary




Recommendation #6 Sialendoscopy should be considered in patients with
RAI induced salivary gland sialadenitis that has not
responded to conservative or medical management or
that is recurrent or chronic in nature.
Strong recommendation, low-quality
evidence
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effective at reducing and sometimes fully alleviating their
symptoms.
8.5 | Ophthalmologic treatment
The treatment of patients found to have dry eye is
focused on ocular surface lubrication with preservative-
free artificial tear replacement drops and gels. Those with
epiphora due to nasolacrimal obstruction can be encour-
aged to undergo dacryocystorhinostomy, in which a sur-
gical bypass is created to allow tear drainage directly
from the lacrimal sac into the nasal cavity, in order to
improve their symptoms and decrease the risk of
dacryocystitis. However, patients should be counseled
that previous RAI treatment decreases the success rate of
dacryocystorhinostomy.110,111
Recommendation #5
In patients experiencing symptoms after RAI expo-
sure timely referral, to an otolaryngologist for salivary
gland and an ophthalmologist for nasolacrimal gland dys-
function, is recommended. [Strong recommendation,
low-quality evidence]
Recommendation #6
Sialendoscopy should be considered in patients with
RAI induced salivary gland sialadenitis that has not
responded to conservative or medical management or
that is recurrent or chronic in nature. [Strong recommen-
dation, low-quality evidence]
9 | FUTURE WORK
The recommendations in this statement are based on the
best available multidisciplinary evidence related to the
adverse sequelae of RAI exposure (Table 2). To date there
are few high-quality, randomized control trials examin-
ing these side effects. Due to the variability in study
design and at times inconclusive data, there is a need to
better understand the true incidence, optimal treatments
and importantly prevention of salivary gland and lacri-
mal dysfunction following RAI use.
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